表紙
市場調查報告書

阿片類藥物疾病:到2028年的機會分析和預測

Opioid Use Disorder - Opportunity Analysis and Forecasts to 2028

出版商 GlobalData 商品編碼 952794
出版日期 內容資訊 英文 116 Pages
訂單完成後即時交付
價格
阿片類藥物疾病:到2028年的機會分析和預測 Opioid Use Disorder - Opportunity Analysis and Forecasts to 2028
出版日期: 2020年07月30日內容資訊: 英文 116 Pages
簡介
阿片類藥物是刺激大腦和神經系統中阿片受體的合成或天然藥物。阿片類藥物通常用於治療疼痛患者。阿片類藥物按規定量服用通常不會導致中毒。阿片類藥物使用障礙(OUD)是一種慢性神經系統疾病,已被描述為反覆強迫使用阿片類藥物和長期自我使用阿片類藥物的結果。隨著大腦適應長期使用阿片類藥物,患者變得更加寬容,需要與原始劑量相似的更高劑量的阿片類藥物來刺激中腦邊緣系統,並且患者繼續接受高劑量的阿片類藥物。您將開始使用毒品。患有OUD的患者有兩個子集。沉迷於用於治療慢性疼痛的醫學類阿片藥物的患者以及沉迷於海洛因和芬太尼等非醫學類阿片藥物的患者。儘管沒有唯一的原因導致OUD,但遺傳和環境因素共同影響著患者。

全球阿片類藥物使用障礙(OUD)市場在10年的預測期內將以8.8%的複合年增長率增長,從八個主要國家的2018年的16億美元增長到2028年的37億美元是期待。預計美國將在2028年繼續保持市場領先地位,銷售額有望達到全球市場的87.7%。

該報告調查並分析了阿片類藥物使用障礙,並提供了有關疾病概述,流行病學,當前治療選擇,未滿足的需求和機會,研發策略,研發評估等的系統信息。

內容

第1章內容

第2章阿片類藥物使用障礙:概述

  • 丁丙諾啡重組促進OUD市場增長
  • 經驗豐富的公司和初創公司以丁丙諾啡處方抗衡
  • 未滿足的環境需求比臨床需求更為重要
  • 後期管道仍專注於改革,早期管道專注於新的MOA
  • 醫生的想法

第3章簡介

  • 催化劑
  • 相關報告
  • 此後的相關報告

第4章疾病概述

  • 病因與病理生理
    • 病因
    • 病理生理學
  • 分類或分級系統

第5章流行病學

第6章當前的治療選擇

  • 概述

第7章未滿足的需求和機會評估

  • 概述
  • 消除進入壁壘
  • 新的行動機制
  • 改善治療指南

第8章研發策略

  • 概述
    • 藥物濫用可能性低
    • 新的行動機制
    • 緩釋製劑,可提高順應性
  • 臨床試驗設計
    • 終點
    • 試用期
    • 比較器臂
    • 患者人數

第9章管道評估

  • 概述
  • 創新的早期方法
  • 其他正在開發的藥物

第10章管道評估分析

  • 主要管道藥物的臨床基準
  • 主要管道藥品的商業基準
  • 競爭力評估
  • 10年最高收入預測
    • 美國
    • 加拿大
    • 歐洲
    • 澳大利亞

第11章附錄

目錄
Product Code: GDHC114POA

Opioids are synthetic or natural agents that stimulate opioid receptors in the brain and nervous system. Opioids are often used to treat patients suffering from pain. When taken in the prescribed quantities, opioids do not generally lead to addiction. Opioid use disorder (OUD) is a chronic neurological disorder that is described as the consequences associated with repeated, compulsive use of opioid drugs, and prolonged self-administration of opioid drugs. As the brain adapts to a prolonged opioid use, the patient's tolerance increases, so a higher dose of opioid is needed to stimulate the mesolimbic system in the same way as the original dose, leading patients to use continued higher doses of the drug. There are two subsets of patients who suffer from OUD: patients who become addicted to medical opioids, which are used to treat chronic pain conditions, and patients who become addicted to non-medical opioids, such as heroin and fentanyl. There is no single cause of OUD, but rather a combination of genetic and environmental factors that influence the patient.

Currently, several drugs have been approved for the treatment of OUD, which can be split into two classes: synthetic opioid receptor agonists (buprenorphine, methadone, morphine, and medical-grade heroin) and opioid antagonists (naltrexone). Many of these drugs have been widely available for decades and are genericized across the markets covered in this report. Some reformulations that have been released more recently, and some are expected to launch during the forecast period, making them a market driver toward the end of the forecast period.

During the 10-year forecast period, the OUD market is expected to grow from $1.6B in 2018 to $3.7B in 2028 in the 8MM, which represents a CAGR of 8.8%. The US is expected to maintain its position as the market leader in 2028, with sales contributing 87.7% to the global market.

The main driver of growth over the forecast period will be the launch of new formulations of buprenorphine, particularly Indivior's Sublocade, which is already launched in the US, Canada, and Australia, as well as Camurus' Buvidal, which is already launched in Europe and Australia. Both are subcutaneous monthly forms of buprenorphine.

There are several drugs that will see their patents expire throughout the forecast period, the most high-profile being Indivior's Suboxone, which is a key barrier of growth in this market. Suboxone, the sublingual buprenorphine + naloxone combination, was the highest-selling drug with sales of $859M in 2018. However, its sales are expected to fall throughout the forecast period at a negative CAGR of 16.9%, due to generic erosion.

Key Questions Answered

  • How will the OUD market landscape in the 8MM (US, Canada, Germany, Austria, Belgium, Denmark, Switzerland, and Australia) change from 2018-2028?
  • What are the most promising late-stage pipeline drugs for OUD?
  • How do the clinical and commercial attributes of late-stage pipeline therapies compare with one another, and against existing treatment options?
  • What are the remaining unmet needs in OUD treatment management?
  • What drivers and barriers will affect OUD therapeutics sales in the 8MM over the forecast period?

Scope

  • Overview of OUD, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
  • Topline OUD market revenue from 2018-2028. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.
  • Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting OUD therapeutics sales in the 8MM.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
  • Analysis of the current and future market competition in the global OUD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the Global OUD market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the OUD therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

1 Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Opioid Use Disorder: Executive Summary

  • 2.1 Reformulations of Buprenorphine Will Drive Growth in the OUD Market
  • 2.2 Experienced and New Players Go Head-to-Head with Buprenorphine Reformulations
  • 2.3 Environmental Unmet Needs of Greater Importance than Clinical Needs
  • 2.4 Late-Stage Pipeline Remains Focused on Reformulations, While Early Stage Pipeline Looks to Novel MOAs
  • 2.5 What Do Physicians Think?

3 Introduction

  • 3.1 Catalyst
  • 3.2 Related Reports
  • 3.3 Upcoming Related Reports

4 Disease Overview

  • 4.1 Etiology and Pathophysiology
    • 4.1.1 Etiology
    • 4.1.2 Pathophysiology
  • 4.2 Classification or Staging Systems

5 Epidemiology

6 Current Treatment Options

  • 6.1 Overview

7 Unmet Needs and Opportunity Assessment

  • 7.1 Overview
  • 7.2 Removal of Access Barriers
  • 7.3 Novel Mechanisms of Action
  • 7.4 Improved Treatment Guidelines

8 R&D Strategies

  • 8.1 Overview
    • 8.1.1 Drug Formulations That Have Less Potential for Abuse
    • 8.1.2 Novel Mechanisms of Action
    • 8.1.3 Extended-Release Formulations That Improve Compliance
  • 8.2 Clinical Trials Design
    • 8.2.1 Endpoints
    • 8.2.2 Trial Duration
    • 8.2.3 Comparator Arms
    • 8.2.4 Patient Population

9 Pipeline Assessment

  • 9.1 Overview
  • 9.2 Innovative Early Stage Approaches
  • 9.3 Other Drugs in Development

10 Pipeline Valuation Analysis

  • 10.1 Clinical Benchmark of Key Pipeline Drugs
  • 10.2 Commercial Benchmark of Key Pipeline Drugs
  • 10.3 Competitive Assessment
  • 10.4 Top-Line 10-Year Forecast
    • 10.4.1 US
    • 10.4.2 Canada
    • 10.4.3 Europe
    • 10.4.4 Australia

11 Appendix

List of Tables

  • Table 1: Opioid Use Disorder: Key Metrics in the 8MM
  • Table 2: Symptoms of Opioid Use Disorder
  • Table 3: Long Term Psychological Impacts of Opioid Use Disorder
  • Table 4: DSM-5 Diagnostic Criteria for Opioid Use Disorder
  • Table 5: Risk Factors and Comorbidities for OUD
  • Table 6: Treatment Guidelines for Opioid Use Disorder
  • Table 7: Leading Treatments for Opioid Use Disorder, 2020
  • Table 8: Vaccines in Development for OUD, 2020
  • Table 9: Drugs in Development for Opioid Use Disorder, 2020
  • Table 10: Clinical Benchmark of Key Pipeline Drugs - OUD
  • Table 11: Commercial Benchmark of Key Pipeline Drugs - OUD
  • Table 12: Key Events Impacting OUD Sales, 2018-2028
  • Table 13: OUD Market - Global Drivers and Barriers, 2018-2028
  • Table 14: Key Historical and Projected Launch Dates for OUD
  • Table 15: Key Historical and Projected Patent Expiry Dates for OUD
  • Table 16: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1: Global Sales Forecast by Country for Opioid Use Disorder, 2018 and 2028
  • Figure 2: Competitive Assessment of the Pipeline Drugs Benchmarked Against the SOC, Suboxone
  • Figure 3: The Impact of Opioid Use Disorder on Brain Function
  • Figure 4: 8MM, 12-Month Total Prevalence of OUD, Men and Women, %, Ages ≥18 Years, 2018
  • Figure 5: 8MM, 12-Month Diagnosed Prevalence of OUD, Men and Women, %, Ages ≥18 Years, 2018
  • Figure 6: 8MM, Sources Used and Not Used to Forecast the 12-Month Total and 12-Month Diagnosed Prevalent Cases of OUD
  • Figure 7: 8MM, Sources Used to Forecast the Severity of 12-Month Total Prevalent Cases of OUD
  • Figure 8: 8MM, Sources Used to Forecast the Severity of 12-Month Diagnosed Prevalent Cases of OUD
  • Figure 9: 8MM, 12-Month Total Prevalent Cases of OUD, Both Sexes, Ages ≥18 Years, N, 2018
  • Figure 10: 8MM, 12-Month Total Prevalent Cases of OUD by Age, N, Both Sexes, 2018
  • Figure 11: 8MM, 12-Month Total Prevalent Cases of OUD by Sex, N, Ages ≥18 Years, 2018
  • Figure 12: 8MM 12-Month Total Prevalent Cases of OUD by Severity, N, Ages ≥18 Years, 2018
  • Figure 13: 8MM, 12-Month Diagnosed Prevalent Cases of OUD, N, Both Sexes, Ages ≥18 Years, 2018
  • Figure 14: 8MM, 12-Month Diagnosed Prevalent Cases of OUD by Age, N, Both Sexes, 2018
  • Figure 15: 8MM, 12-Month Diagnosed Prevalent Cases of OUD by Sex, N, Ages ≥18 Years, 2018
  • Figure 16: 8MM, 12-Month Diagnosed Prevalent Cases of OUD by Severity, N, Ages ≥18 Years, 2018
  • Figure 17: Unmet Needs and Opportunities in Opioid Use Disorder
  • Figure 18: Overview of the Development Pipeline in Opioid Use Disorder
  • Figure 19: Key Trials for the Promising Pipeline Agents Profiled by GlobalData in the Associated Excel File
  • Figure 20: Competitive Assessment of Pipeline Drugs Benchmarked Against the SOC, Suboxone
  • Figure 21: 8MM, OUD Sales Forecast by Country, 2018 and 2028
  • Figure 22: 8MM, OUD Sales Forecast by Class, 2018 and 2028
  • Figure 23: US OUD Sales Forecast by Class, 2018 and 2028
  • Figure 24: Canada OUD Sales Forecast by Class, 2018 and 2028
  • Figure 25: Europe OUD Sales Forecast by Country, 2018 and 2028
  • Figure 26: Europe OUD Sales Forecast by Class, 2018 and 2028
  • Figure 27: Australia OUD Sales Forecast by Class, 2018 and 2028